Overview

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine which treatment is more effective and safer for the patients in COPD C group with bronchiectasis.The research results will help guide physicians to select appropriate individualized treatment and hopefully provide some evidence-based medicine proofs for revising guide.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Treatments:
Bromides
Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate
Tiotropium Bromide